At an interim analysis of the phase 3 LITESPARK-011 trial (NCT04586231), the oral combination of belzutifan (Welireg) plus ...

Experts discuss the integration of GLP-1 receptor agonists in treating neuroendocrine tumors, highlighting safety concerns and the need for further research.

An exosome-based treatment of glioblastoma multiforme (GBM) has received orphan drug designation from the FDA. 1 Exousia AI, ...

Somatostatin analogs (SSAs) like octreotide LAR and lanreotide are essential in managing NETs. Standard practice involves ...

A groundbreaking study reveals promising efficacy and safety of 212Pb-DOTAMTATE for treating neuroendocrine tumors, paving ...

CUTNETs aims to improve surgical evidence for NETs by identifying high-risk patients and developing resectability criteria. Collaboration is essential due to the uncommon nature of NETs and the need ...

Rosen's excitement about AI stems from the ability to move beyond population health theories to deliver truly individualized ...

For lenvatinib (Lenvima), which can cause hypertension, patients’ baseline blood pressure should be considered, and they should be monitored for the first 4 to 6 weeks. He recommends oncologists ...

FDA designates ZEN-3694 as an orphan drug, offering hope for patients with NUT carcinoma with no current approved therapies. The FDA has granted orphan drug designation to ZEN-3694, a novel oral ...

AI transforms cancer treatment by personalizing care and enhancing patient-provider communication, revolutionizing how patients manage their health.